Literature DB >> 7642616

Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics.

M Tsiang1, C S Gibbs, L C Griffin, K E Dunn, L L Leung.   

Abstract

The thrombin aptamer is a single-stranded DNA of 15 nucleotides that was identified by the selection of thrombin-binding molecules from a large combinatorial library of oligonucleotides. This prototype aptamer of thrombin has a unique double G-tetrad structure capable of inhibiting thrombin at nanomolar concentrations through binding to a specific region within thrombin exosite I. Substitution of arginine 70 in thrombin exosite I with glutamic acid effectively eliminated binding of the prototype thrombin aptamer. In contrast, aptamers selected against R70E thrombin were able to bind and inhibit both wild-type and R70E thrombins, and displayed potassium-independent inhibition. Aptamers selected against R70-E thrombin bound to sites identical or overlapping with that of the prototype thrombin aptamer. These aptamers retained the potential to form double G-tetrad structures; however, these structures would be destabilized by a T-->A substitution, disrupting the T4-T13 base pairing found in the prototype. This destabilization appeared to be partially compensated by newly recruited structural elements. Thus, selection against R70E thrombin did not lead to aptamers that bound to alternative sites, but instead to ssDNA structures with a suppressor mutation that accommodated the mutation in thrombin within a double G-tetrad context. These results provide insight into the aptamer-thrombin interaction and suggest that the binding site for the prototype is the dominant aptamorigenic site on thrombin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642616     DOI: 10.1074/jbc.270.33.19370

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Cytokine detection by antibody-based proximity ligation.

Authors:  Mats Gullberg; Sigrún M Gústafsdóttir; Edith Schallmeiner; Jonas Jarvius; Mattias Bjarnegård; Christer Betsholtz; Ulf Landegren; Simon Fredriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-21       Impact factor: 11.205

2.  Stability and binding properties of a modified thrombin binding aptamer.

Authors:  Bruno Pagano; Luigi Martino; Antonio Randazzo; Concetta Giancola
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

Review 3.  Functional nucleic acid sensors.

Authors:  Juewen Liu; Zehui Cao; Yi Lu
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

4.  A combined atomic force/fluorescence microscopy technique to select aptamers in a single cycle from a small pool of random oligonucleotides.

Authors:  Lu Peng; Bryan J Stephens; Keith Bonin; Roger Cubicciotti; Martin Guthold
Journal:  Microsc Res Tech       Date:  2007-04       Impact factor: 2.769

5.  High-resolution structures of two complexes between thrombin and thrombin-binding aptamer shed light on the role of cations in the aptamer inhibitory activity.

Authors:  Irene Russo Krauss; Antonello Merlino; Antonio Randazzo; Ettore Novellino; Lelio Mazzarella; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2012-06-04       Impact factor: 16.971

6.  A novel method of screening thrombin-inhibiting DNA aptamers using an evolution-mimicking algorithm.

Authors:  Kazunori Ikebukuro; Yuji Okumura; Koichi Sumikura; Isao Karube
Journal:  Nucleic Acids Res       Date:  2005-07-07       Impact factor: 16.971

7.  Effect of locked-nucleic acid on a biologically active g-quadruplex. A structure-activity relationship of the thrombin aptamer.

Authors:  Laura Bonifacio; Frank C Church; Michael B Jarstfer
Journal:  Int J Mol Sci       Date:  2008-03-24       Impact factor: 6.208

Review 8.  Splitting aptamers and nucleic acid enzymes for the development of advanced biosensors.

Authors:  Mégane Debiais; Amandine Lelievre; Michael Smietana; Sabine Müller
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.